Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cybin ( (TSE:CYBN) ) has shared an announcement.
On October 28, 2025, Cybin Inc. announced a registered direct offering of 22,277,750 common shares and 4,605,500 pre-funded warrants, raising approximately US$175 million. The offering, which closed on October 31, 2025, aims to repay outstanding convertible debentures and fund the company’s CYB003, CYB004, and CYB005 programs, as well as general corporate purposes. This strategic move is expected to bolster Cybin’s financial position and advance its clinical programs, potentially strengthening its market position in the neuropsychiatry industry.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$45.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin Inc. is a Phase 3 clinical-stage neuropsychiatry company focused on revolutionizing mental healthcare through the development of innovative treatment options for mental health conditions. The company is advancing its proprietary drug discovery platforms and delivery systems to address the unmet needs of patients with mental health disorders.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.92M
See more data about CYBN stock on TipRanks’ Stock Analysis page.